A Point-of-Care Cytomegalovirus Serodiagnostic and Avidity Assay
$223,834N43FY2017AINIH
Luna Innovations, Inc., Roanoke VA
Investigators
Abstract
To adapt current technology for detection of CMV IgM and IgG antibodies, as well as IgG avidity at the point-of-care.
View original record on NIH RePORTER →